NewsJuly 25, 2013
Ziarco appoints David L. Brinkley to the Board of Directors
March 18, 2013
John L. LaMattina, Ph.D. - Strategic R&D Advisor
November 5, 2012
Ziarco Secures Series A Funding
Ziarco has 4 major development programmes staffed by highly experienced drug development professionals.
By exploiting shared pathobiology in inflammatory & allergic pathways, coupled with high human confidence in rationale, Ziarco's programmes can be used to treat multiple disorders affecting the airways, skin and other organs.
Ziarco intends to progress its programmes through clinical proof-of-concept studies using creative drug development strategies and partnerships.